Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syndax Pharmaceuticals Inc.

www.syndax.com

Latest From Syndax Pharmaceuticals Inc.

Pipeline Watch: LentiGlobin, BMS-986205 Phase III Studies Initiated

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m

Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.

Financing Business Strategies

Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan

Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Syndax Pharmaceuticals Inc.
  • Senior Management
  • Briggs W Morrison, MD, CEO
    Richard P Shea, CFO
    Michael A Metzger, Pres. & COO
    Peter Ordentlich, PhD, CSO
    Michael Meyers, MD, PhD, CMO
  • Contact Info
  • Syndax Pharmaceuticals Inc.
    Phone: (781) 419-1400
    35 Gatehouse Dr.
    Bldg D, Floor 3
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register